| Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation M Gamalo‐Siebers, J Savic, C Basu, X Zhao, M Gopalakrishnan, A Gao, ... Pharmaceutical Statistics 16 (4), 232-249, 2017 | 84 | 2017 |
| Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from … M Sebag, NS Raje, NJ Bahlis, C Costello, B Dholaria, M Solh, MY Levy, ... Blood 138, 895, 2021 | 49 | 2021 |
| Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a phase I study of PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients … NS Raje, A Jakubowiak, C Gasparetto, RF Cornell, HI Krupka, D Navarro, ... Blood 134, 1869, 2019 | 47 | 2019 |
| Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). NJ Bahlis, NS Raje, C Costello, BR Dholaria, MM Solh, MY Levy, ... Journal of Clinical Oncology 39 (15_suppl), 8006-8006, 2021 | 41 | 2021 |
| Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody … AM Lesokhin, MY Levy, AP Dalovisio, NJ Bahlis, M Solh, M Sebag, ... Blood 136, 8-9, 2020 | 37 | 2020 |
| Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma N Raje, NJ Bahlis, C Costello, B Dholaria, M Solh, MY Levy, ... Blood 140 (Supplement 1), 388-390, 2022 | 31 | 2022 |
| Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial NJ Bahlis, CL Costello, NS Raje, MY Levy, B Dholaria, M Solh, ... Nature medicine 29 (10), 2570-2576, 2023 | 20 | 2023 |
| Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1. AJ Jakubowiak, NJ Bahlis, NS Raje, C Costello, BR Dholaria, MM Solh, ... Journal of Clinical Oncology 40 (16_suppl), 8014-8014, 2022 | 16 | 2022 |
| A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo’s oil C Basu, MA Ahmed, RV Kartha, RC Brundage, GV Raymond, JC Cloyd, ... Journal of biopharmaceutical statistics 26 (6), 1025-1039, 2016 | 12 | 2016 |
| A model‐based approach to assess the exposure–response relationship of Lorenzo's oil in adrenoleukodystrophy MA Ahmed, RV Kartha, RC Brundage, J Cloyd, C Basu, BP Carlin, ... British Journal of Clinical Pharmacology 81 (6), 1058-1066, 2016 | 10 | 2016 |
| First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2 … TA Yap, A Giordano, EP Hamilton, P LoRusso, M Bowers, C Basu, ... Journal of Clinical Oncology 41 (16_suppl), 3009-3009, 2023 | 8 | 2023 |
| P897: updated results from the ongoing phase 1 study of Elranatamab, a BCMA targeted t-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma A Dalovisio, N Bahlis, N Raje, C Costello, B Dholaria, M Solh, M Levy, ... HemaSphere 6, 788-789, 2022 | 5 | 2022 |
| A phase 1 dose-escalation study of PF-06671008, a bispecific T-cell-engaging therapy targeting P-cadherin in patients with advanced solid tumors JJ Harding, I Garrido-Laguna, X Chen, C Basu, A Dowlati, A Forgie, ... Frontiers in immunology 13, 845417, 2022 | 4 | 2022 |
| Abstract P5-16-06: A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients … TA Yap, C Basu, JW Goldman, M Gordon, E Hamilton, A Kelly, F Liu, ... Cancer Research 82 (4_Supplement), P5-16-06-P5-16-06, 2022 | 4 | 2022 |
| MM-379: MagnetisMM-1: a study of elranatamab (PF-06863135), a B-Cell maturation antigen (BCMA)-targeted, CD3-engaging bispecific antibody, for patients with relapsed or … M Levy, N Bahlis, N Raje, C Costello, B Dholaria, M Solh, M Tomasson, ... Clinical Lymphoma Myeloma and Leukemia 21, S439, 2021 | 4 | 2021 |
| Bayesian hierarchical models for data extrapolation and analysis in pediatric disease clinical trials B Cynthia, BP Carlin Bayesian methods in pharmaceutical research, 259-270, 2020 | 2 | 2020 |
| A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or … TA Yap, C Basu, JW Goldman, M Gordon, E Hamilton, A Kelly, F Liu, ... CANCER RESEARCH 82 (4), 2022 | 1 | 2022 |
| Confidence Intervals for Discrete Data in Clinical Research V Pradhan, A Gangopadhyay, SM Menon, C Basu, T Banerjee Chapman and Hall/CRC, 2021 | 1 | 2021 |
| OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (PTS) with relapsed or … B Dholaria, N Bahlis, N Raje, C Costello, M Solh, M Levy, M Tomasson, ... Clinical Lymphoma Myeloma and Leukemia 21, S17, 2021 | 1 | 2021 |
| Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism C Basu, X Ma, M Mo, HA Xia, R Brundage, M Al‐Kofahi, BP Carlin Pharmaceutical statistics 19 (6), 882-896, 2020 | 1 | 2020 |
